October 1, 2001Diabetic Medicine

Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low‐density lipoprotein subfraction levels

View Full Paper

Ask AI

Bookmark

Why the study?

Does acute glibenclamide administration improve postprandial hypertriglyceridaemia in Type 2 diabetic patients?

Population

8 randomly selected Type 2 diabetic individuals, aged 43-65 years, who had never received any anti-diabetic…

Comparison

5 mg glibenclamide oral once, administered with… vs Placebo administered with a 485 kcal mixed meal

Design

RCT, random order (crossover design)

Follow-up

6 hours

Authors

ISIoanna SkrapariEvangelismos Hospital ΔΠΔέσποινα ΠερρέαNational and Kapodistrian University of Athens IIIoannis IoannidisHygeia Hospital

Discussion

Member takes

Implication

Supports acute glibenclamide for postprandial lipid control in T2D; extends sulfonylurea benefits to intestinal triglyceride reduction.

Structured PICO

Does acute glibenclamide administration improve postprandial hypertriglyceridaemia in Type 2 diabetic patients?

Population

8 randomly selected Type 2 diabetic individuals, aged 43-65 years (mean, 54 years), who had never received any anti-diabetic drug.

Intervention

5 mg glibenclamide oral once, administered with a 485 kcal mixed meal

Comparator

Placebo administered with a 485 kcal mixed meal

Outcome

Postprandial lipaemia (total triglyceride levels in plasma, chylomicrons, VLDL subfractions, and IDL) measured at 2, 4, and 6 hours after meal consumptionsurrogate

Acute glibenclamide administration improves postprandial hypertriglyceridaemia by reducing triglycerides of intestinal origin in patients with Type 2 diabetes.

Cite This Study

Skrapari et al. (2001) studied this question.

synapsesocial.com/papers/6a7078d335aa2c282ce1cb05 https://doi.org/10.1046/j.1464-5491.2001.00538.x

View Full Paper

Ask AI

Bookmark

Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low‐density lipoprotein subfraction levels

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low‐density lipoprotein subfraction levels

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider